This bill tasks the Secretary of Health and Human Services—acting through NIH and HRSA—to make PMDD a named research and public‑health priority. It requires expanded NIH research (including clinical trials and mandates on participant diversity), new federal surveillance and data publication on PMDD prevalence and economic impact, a federally run public‑awareness campaign, continuing medical education for clinicians, and competitive grants to accredited training programs to build clinical capacity.
The measure also requires a Congress-facing progress report within two years and authorizes appropriations across multiple fiscal windows. For health systems, training institutions, and clinicians, the bill creates planning and funding opportunities; for patients it aims to reduce underdiagnosis and stigma—but it does not change coverage rules or create new benefit mandates.
At a Glance
What It Does
The bill directs NIH to expand and intensify PMDD research, funds clinical trials, and requires collection and publication of prevalence, economic, and access data. It charges HHS with a public‑health awareness campaign and HRSA with producing and distributing continuing medical education, and it creates grant authority for accredited clinical training programs.
Who It Affects
Directly affected entities include NIH and HRSA (program design and administration), accredited medical, nursing, and pharmacy schools, residency and fellowship programs, nonprofit hospitals, and clinical researchers; patients assigned female at birth of reproductive age and clinicians diagnosing or treating PMDD will see downstream effects. Congress receives a mandated progress report to inform oversight.
Why It Matters
The bill formally elevates PMDD in federal research and education priorities, builds an evidence base on prevalence and economic impact, and aims to grow the clinical workforce capable of diagnosing and treating PMDD—shifting federal attention from discrete advocacy toward programmatic investment and data generation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Act creates three interlocking strands: research, education/awareness, and workforce training. For research, it directs the Secretary (through NIH) to expand studies of PMDD causes, risk factors, diagnosis, and treatment, to support clinical trials, and to require study populations that reflect racial, ethnic, and socioeconomic diversity.
The statute also directs HHS to collect and publish national data on PMDD prevalence, incidence, economic and workforce impacts, and barriers to care.
On awareness and provider education, the bill requires HHS to run a public‑health campaign targeted at patients and clinicians to raise symptom recognition, reduce stigma, and encourage timely care. HRSA must develop and disseminate continuing medical education materials that help clinicians distinguish PMDD from other mental‑health and gynecological conditions and provide evidence‑based care.To expand clinical capacity, the bill creates a competitive grant program to help accredited schools, residency programs, hospitals, and related training programs develop or expand PMDD‑focused clinical training—this includes physicians, nurses, nurse practitioners, physician assistants, pharmacists, and social workers.
The grant language explicitly lists eligible institution types and directs outreach to expand training opportunities that also address mid‑life women’s health, perimenopause, and menopausal symptoms.Finally, the Secretary must submit a progress report to Congress within two years documenting expanded research, improvements in awareness and education, and increased access to diagnosis and treatment. Each substantive title carries an authorization of appropriations for specified fiscal‑year windows, but appropriations are phrased as “such sums as necessary.” The bill stops short of altering insurance coverage, benefit mandates, or regulatory definitions of PMDD.
The Five Things You Need to Know
The bill requires NIH to expand PMDD research and to support clinical trials while ensuring study populations include diverse racial, ethnic, and socioeconomic groups.
HHS must collect and publish data on PMDD prevalence, incidence, economic and workforce impacts, and barriers to diagnosis and treatment.
HHS will fund and run a public‑health awareness campaign and HRSA will develop and disseminate continuing medical education focused on accurate diagnosis and differentiation of PMDD.
The statute creates competitive grant authority for accredited medical, nursing, pharmacy schools, residency and nurse practitioner programs, nonprofit hospitals, and related training programs to build PMDD clinical training capacity.
The Secretary must report to Congress within two years on progress across research, education, and access, and the bill authorizes appropriations for discrete fiscal‑year windows (sections vary between FY2026–2030 and FY2027–2031).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings establishing PMDD as a public‑health issue
This short findings section frames PMDD as a severe, often disabling condition affecting an estimated 5–8% of women and people assigned female at birth of reproductive age, and identifies underdiagnosis, under‑research, and stigma as core problems. While not operative law, the findings set congressional intent that guides how agencies prioritize program design and reporting metrics.
NIH research expansion and national surveillance
This section directs the Secretary—through NIH—to expand basic and clinical PMDD research, fund clinical trials, and require adequate demographic representation in studies. Practically, NIH will need to issue funding opportunities, adjust study inclusion criteria, and coordinate with existing reproductive‑mental health portfolios. The section also mandates HHS data collection and public reporting on prevalence, economic/workforce impact, and access barriers, which will require definition of case ascertainment standards, sampling strategies, and likely collaboration with CDC, health surveys, and administrative data sources.
Public awareness campaign and provider education
HHS must design and implement a public‑health awareness campaign to raise patient and provider recognition and reduce stigma. HRSA gets a concrete education role: develop and disseminate CME materials to help clinicians correctly diagnose PMDD and distinguish it from overlapping psychiatric or gynecologic conditions. The statute also requires coordination with existing HHS programs, which aims to avoid duplicative messaging but places a coordination burden on program offices.
Grants to expand clinical training capacity
This grant program authorizes competitive awards to a defined list of eligible entities—accredited schools of medicine, nursing, pharmacy, nonprofit hospitals, residency and nurse practitioner programs, and related training programs—to develop or expand PMDD training. The provision explicitly includes training for a broad set of clinicians and requires outreach to expand opportunities that also address perimenopause and menopausal care, potentially widening the scope of funded curricula and clinical placements.
Congressional progress report and appropriations
The Secretary must submit a report to Congress within two years evaluating progress on research expansion, awareness/education, and access to diagnosis and treatment. Each major program carries an authorization of appropriations for specified fiscal years, but the language is open‑ended (“such sums as necessary”), leaving actual funding levels to subsequent appropriation decisions and to agency budgeting choices.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Individuals with PMDD: expected improvements in diagnosis, treatment options, and public awareness that could reduce stigma and delay to care.
- Clinical trainees and practitioners: new CME and grant‑funded training programs will increase clinician familiarity with PMDD and strengthen diagnostic skills across primary care and specialties.
- Researchers and academic centers: dedicated NIH emphasis and clinical‑trial support expands funding opportunities and creates incentives for multidisciplinary PMDD research.
- Medical and allied health training programs: eligible schools, residency programs, and hospitals can receive grant funding to develop curriculum and clinical training slots focused on PMDD.
- Employers and workforce planners: improved data on economic and workforce impacts will give employers and policymakers evidence to design workplace supports and estimate productivity effects.
Who Bears the Cost
- HHS and operating agencies (NIH, HRSA, CDC): responsible for program design, grant management, surveillance, and campaign execution, requiring administrative capacity and appropriated funds.
- Taxpayers/federal budget: the bill authorizes appropriations without fixed amounts, meaning funding will increase discretionary spending pressure if appropriated.
- Academic institutions and hospitals applying for grants: must allocate staff time to prepare applications, meet reporting requirements, and potentially augment training sites or preceptor capacity.
- Researchers and study sites: obligations to recruit demographically representative samples may raise trial costs and complicate timelines.
- Clinician groups not prioritized by funding: resources devoted to PMDD training may compete with other continuing education priorities within limited institutional training budgets.
Key Issues
The Core Tension
The bill confronts a genuine trade‑off: it seeks to elevate a frequently overlooked medical condition through research, data, and training, but it does so without guaranteed funding levels or changes to payer coverage—so the initiative can improve knowledge and clinician capacity while still leaving many patients without affordable access to the care the bill’s programs identify as needed.
The bill creates program authorities without specifying funding levels; each program is authorized “such sums as necessary,” so actual impact depends on appropriations choices. That makes the statute an enabling framework rather than a guarantee of expanded services or research.
Agencies will need to define clinical case criteria and surveillance methods; differences in diagnostic approaches to PMDD could affect prevalence estimates and comparability across studies.
Requiring diverse representation in trials is important but operationally difficult—recruitment, retention, and culturally appropriate study design increase cost and complexity. The awareness campaign and CME may change clinical practice patterns, but the statute does not address insurance coverage or reimbursement for PMDD evaluation or treatments; increased diagnosis could therefore create demand that patients cannot afford.
Finally, coordination requirements across HHS programs reduce duplication risk but create managerial complexity and potential turf fights between offices with overlapping maternal/reproductive mental‑health portfolios.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.